Our institute creates solutions for enduring health and quality of life across cultural and ethnic diversity. Through integration of faculty involved in state-of-the-art clinical care, cutting-edge research, innovative educational and training models, and community engagement, we have created a unique environment attracting NIH and private support for clinical trials. Listed below are ongoing trials supported by the IHA.
Research and clinical trials
The use of duloxetine for cognition improvement in individuals with mild cognitive impairment (DEMO):
The purpose of this study is to determine whether Cymbalta (duloxetine) is effective to improve cognition in individuals with Mild Cognitive Impairment. ClinicalTrials.gov Identifier: NCT02590874
This is a randomized, double blinded, placebo controlled clinical trial. Participants will be randomized into one of two study groups (placebo-control group and Duloxetine group). Participants in the Duloxetine group will receive up to 60mg of an FDA approved antidepressant, Duloxetine. Participants in the control group will receive a placebo that is the exact shape and size of the study drug.
We will recruit male or female participants, age 50 and up, from the Health and Aging Brain study, with a MCI diagnoses, and at least 2 or more yes answers in 5 specific items of the Geriatric Depression Scale.
Pregnant or breastfeeding women, subjects with glaucoma, duloxetine hypersensitivity, or with history of a psychiatric disorder, stroke, and drug or alcohol abuse are not eligible. If a subject is accepted to the trial, he/she will be expected to stay in the study for a minimum of sixth months, take the study drug as indicated, and complete up to 8 visits.
If interested, call 817-735-2968 to set an appointment.
Health and Aging Brain among Latino Elders (HABLE):
HABLE places an emphasis on studying aging among Mexican Americans in Texas. Factors such as diabetes, physical conditions, lifestyle and memory and thinking problems differ among groups. Studying healthy and unhealthy aging in the Mexican American culture will hopefully allow us to create better intervention and treatment programs.
Participants will be compensated for their time and effort.
For more information, contact Haydee Izurieta, (817) 735-2963
Health and Aging Brain Study (HABS):
The goal of the Health and Aging Brain Study is to better understand the biological and lifestyle factors that influence memory and thinking as we age. Current enrollment is limited to 50 and older.
Participants may be asked questions about medical history, social and physical activity, diet, mood, and other related things. They may have a brief medical examination, have a blood test, and complete testing of memory and thinking.
For more information, contact Haydee Izurieta, (817) 735-2963
A Study of LY3314814 in Participants With Mild Alzheimer’s Disease Dementia (DAYBREAK-ALZ):
The purpose of this study is to evaluate the efficacy of the drug LY3314814 in participants with mild Alzheimer’s disease (AD) dementia. We will recruit male or female participants between the ages of 55 to 85 inclusive with an MMSE score of 20-26 inclusive. ClinicalTrials.gov Identifier: NCT02783573.
If interested, call or email, Wilma Burns, (817)735-0647, firstname.lastname@example.org.
Texas Alzheimer’s Research Care Consortium:
The Texas Alzheimer’s Research and Care Consortium (TARCC) is currently recruiting persons age 50 or older with Alzheimer’s disease (AD) and mild cognitive impairment (MCI) to participate in TARCC research studies. TARCC is also recruiting adults with normal cognition to serve as research “control” study participants.
All TARCC research participants receive memory testing and blood is drawn to collect samples for genetic, biomarker and laboratory analyses and to bank for use in addressing current and future research questions. A complete follow-up examination is conducted annually for all research participants. Research participants receive an annual $100 stipend for participation in the study.
For more information, contact Lisa Alvarez, MA, TARCC Project Coordinator, (817) 735-0275, email@example.com.
Dr. Vicki Nejtek (Principal Investigator) in the Family Medicine Department is recruiting men between the ages of 18 and 80 who have completed at least a bachelor’s degree to participate in a study to help identify novel risk factors for TIA/stroke in young adults in comparison to older adults. The study will take about one hour and you will be asked to complete a set of surveys and have various body measurements taken.
For more information and to see if you are eligible to participate, please call Ranna Al-Dossari at (817) 735-7689 or e-mail: firstname.lastname@example.org.
Exercise in Adults With Mild Memory Problems (EXERT):
This study will evaluate the effects of physical exercise on cognition, functional status, brain atrophy and blood flow, and cerebrospinal fluid biomarkers of Alzheimer’s disease in adults with amild memory impairment. Half of participants will participate in a stretching-balance-range of motion exercise program, while the other half will participate in a moderate/high aerobic training program.
We will recruit male or female participants between the ages of 65-89 inclusive with a MCI diagnosis. ClinicalTrials.gov Identifier: NCT02814526
CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer’s Disease (AD):
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The final efficacy and safety assessment will be performed 52 weeks after the last crenezumab dose.
We will recruit male or female participants between the ages of 50 to 85 inclusive with an MMSE score of 22 or above. ClinicalTrials.gov Identifier: NCT02670083
If interested, call or email, Isabel Vecino, (817)735-0304, email@example.com
This page was last modified on July 31, 2017